Back
Milestone Pharmaceuticals 10K Form
Sell
50
MIST
Milestone Pharmaceuticals
Last Price:
1.86
Seasonality Move:
-2.66%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-08-12 | 10Q | MIST/Milestone Pharmaceuticals Quarterly |
| 2020-05-14 | 10Q | MIST/Milestone Pharmaceuticals Quarterly |
| 2020-03-06 | 10K | MIST/Milestone Pharmaceuticals Annual |
| 2019-11-13 | 10Q | MIST/Milestone Pharmaceuticals Quarterly |
| 2019-08-13 | 10Q | MIST/Milestone Pharmaceuticals Quarterly |
| 2019-06-19 | 10Q | MIST/Milestone Pharmaceuticals Quarterly |
Receive MIST News And Ratings
See the #1 stock for the next 7 days that we like better than MIST
MIST Financial Statistics
Sales & Book Value
| Annual Sales: | $1M |
|---|---|
| Cash Flow: | $-7.02M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.45 |
| Price / Book: | 3.78 |
Profitability
| EPS (TTM): | -0.81000 |
|---|---|
| Net Income (TTM): | $-42.77M |
| Gross Margin: | -- |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Milestone Pharmaceuticals Earnings Forecast
Key Milestone Pharmaceuticals Financial Ratios
- The Research & Development expenses have been 3,105.20% of Revenue.
- The Interest Expense is -4.28% of Operating Income.
- The Net Earning history of MIST is -5,968.50% of Total Revenues.
- Per Share Earnings over the last 7 years have been positive in 2 years.
Milestone Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | MIST |
| CUSIP: | 59935V |
| Website: | milestonepharma.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
MIST Technical Analysis vs Fundamental Analysis
Sell
50
Milestone Pharmaceuticals (MIST)
is a Sell
Is Milestone Pharmaceuticals a Buy or a Sell?
-
Milestone Pharmaceuticals stock is rated a Sell
The current Milestone Pharmaceuticals [MIST] share price is $1.86. The Score for MIST is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.